Mission Bio updates platform to expand heme-onc research

By The Science Advisory Board staff writers

September 8, 2021 -- Mission Bio has improved its Tapestri platform to expand its accessibility and utility in hematologic oncology (heme-onc) research.

The updates allow researchers to apply single-cell analysis to a wider range of projects due to new ready-to-use panels, Tapestri single-cell DNA published panels, and a lowered input threshold. Researchers now can access single-cell insights from as few as 20,000 cells while conserving samples.

BioLegend's expanded TotalSeq D antibodies catalog has also been added to Tapestri. The addition enables researchers to start with a predesigned heme-onc panel (or customize one to fit the needs of a specific project) and connect genomic data to a broader array of phenotypes, according to the firm.

Mission Bio is hosting a virtual launch event of its platform on September 21, 2021, at 8 a.m. Pacific time.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here